Page 69 - Read Online

Page 16 of 25 Torres et al. J Cancer Metastasis Treat 2018;4:4 I http://dx.doi.org/10.20517/2394-4722.2017.49

Table 3. Current clinical trials to evaluate bacteria use in cancer treatment
Bacterium Indicaction Clinical phase NCT identification
Clostridium novyi-NT Patients with malignant solid tumors refractory to treatment Phase I NCT01924689
Lm-LLO-E7 Patients with grade 2 cervical intraepithelial neoplasia Phase II NCT01116245
Patients with non-small cell lung carcinoma, HPV positive Phase II NCT02531854
Patients with anorectal carcinoma Phase II NCT02399813
Patients with HPV positive oropharyngeal cancer Phase II NCT02002182
Patients with high risk of locally advanced cervical cancer Phase III NCT02853604
CRS-207 Adults with previously treated pancreatic adenocarcinoma Phase II NCT02004262
Patients with malignant pleural mesothelioma Phase I NCT01675765
Patients with ovarian or peritoneal cancer Phase I/II NCT02575807
ADU-623 Patients with astrocytic tumors Phase I NCT01967758
ADXS31-142 Patients with prostate cancer Phase I/II NCT02325557
HPV: human papilloma virus

DECLARATIONS
Authors’ contributions
Article conception and design: Olivar LC, Lameda V, Torres W
Acquisition and analysis of bibliographic information: Torres W, Martinez MS, Lameda V, Olivar LC,
Navarro C, Fuenmayor J, Pérez A, Rojas M
Drafting of the manuscript: Torres W, Martinez MS, Lameda V, Olivar LC, Navarro C, Fuenmayor J, Pérez A,
Rojas M, Rojas J
Critical revision and final approval: Bermúdez V, Velasco M, Mindiola A, Rojas J

Financial support and sponsorship
None.

Conflict of interests
The authors have no conflict of interest.

Patient consent
Not applicable.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Ministery of Health. Bolivarian Republic of Venezuela. Anuary of Mortality 2013. Available from: http://www.ovsalud.org/descargas/
publicaciones/documentos-oficiales/Anuario-Mortalidad-2013.pdf [Last accessed on 19 Jan 2018].
3. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin
Oncol 2013;25:50-1.
4. Burrell R, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature
2013;501:338-45.
5. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108:479-85.
6. Spratt D, Pei X, Yamada J, Kollmeier M, Cox B, Zelefsky M. Long-term survival and toxicity in patients treated with high-dose
intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013;85:686-92.
7. Senn H. Gallen consensus 2013: optimizing and personalizing primary curative therapy of breast cancer worldwide. Breast Care